U.S. Pharmaceuticals & Biotech Buy the Dip

Celldex Therapeutics

Market Cap: US$2.8b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

Vera Therapeutics

Market Cap: US$2.7b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Taysha Gene Therapies

Market Cap: US$1.8b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

COMPASS Pathways

Market Cap: US$1.6b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Annexon

Market Cap: US$883.1m

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Design Therapeutics

Market Cap: US$753.2m

A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Neurogene

Market Cap: US$730.9m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Rigel Pharmaceuticals

Market Cap: US$727.3m

A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

Immix Biopharma

Market Cap: US$681.3m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Prelude Therapeutics

Market Cap: US$400.7m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Sutro Biopharma

Market Cap: US$381.1m

Operates as an oncology company.

Opus Genetics

Market Cap: US$252.7m

A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.

Precision BioSciences

Market Cap: US$196.6m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Karyopharm Therapeutics

Market Cap: US$178.2m

A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

PepGen

Market Cap: US$146.6m

A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

Kalaris Therapeutics

Market Cap: US$96.1m

A clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.

Cypherpunk Technologies

Market Cap: US$78.7m

A privacy technology company, implements a digital asset strategy anchored by Zcash in the United States.

Talphera

Market Cap: US$67.0m

A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.